Hemorrhagic cytitis after bone marrow transplantation.

Area of Science:

• Hematology
• Virology
• Oncology

Background:

• Hemorrhagic cystitis (HC) is a significant complication post-bone marrow transplantation (BMT), occurring in 13-38% of patients.
• HC presents with symptoms such as gross hematuria, bladder pain, and urinary frequency.
• Understanding the characteristics of HC post-hematopoietic stem cell transplantation (HSCT) is crucial for patient management.

Purpose of the Study:

• To investigate the clinical characteristics of patients who developed hemorrhagic cystitis after hematopoietic stem cell transplantation.
• To identify potential risk factors and outcomes associated with HC in this patient population.

Main Methods:

• A retrospective chart review was conducted for patients undergoing BMT between January 1996 and August 2012.
• Data collected included patient demographics, diagnosis, conditioning regimen, time to HC development, and treatment interventions.
• Analysis focused on identifying patterns and associations within the studied cohort.

Main Results:

• Out of 500 BMT patients, 52 developed HC, with a mean age of 39 years (34 males, 18 females).
• Common diagnoses included AML, ALL, CML, MDS, and others; HC onset averaged 59.48 days post-BMT.
• Mortality was 51.14%, though HC was not the direct cause; polyomaviruses were detected in 78.94% of survivors.

Conclusions:

• Polyomavirus (BK and JC types) reactivation, facilitated by immunosuppression, is a likely cause of HC post-HSCT.
• Differential diagnoses for HC include other infections, lithiasis, thrombocytopenia, and drug toxicity.
• The urologist's role in managing HC post-HSCT is limited, with viral factors being primary drivers.